Igbinosa Irogue, Berube Caroline, Lyell Deirdre J
Stanford University, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine.
Stanford University, Department of Medicine, Division of Hematology, Stanford, California, USA.
Curr Opin Obstet Gynecol. 2022 Apr 1;34(2):69-76. doi: 10.1097/GCO.0000000000000772.
Anemia in pregnancy is associated with increased maternal and neonatal morbidity. There is increasing awareness amongst obstetricians about the need to screen for iron deficiency anemia (IDA), as well as growing literature on diagnosis and treatment. This review aims to summarize causes, consequences, treatment, and evaluation of IDA in pregnancy.
National guidelines provide varying guidance on diagnosis and treatment of IDA in pregnancy. Serum ferritin is a helpful adjunct for the diagnosis of IDA. Oral iron remains an option for treatment; absorption is improved with every other day dosing and is effective for patients able to tolerate. Emerging studies on modern generations of intravenous (IV) iron demonstrate shorter infusion times and improved safety profiles. Notably, recent UK guidelines provide consideration for universal IV iron supplementation for treatment of anemia beyond 34 weeks of pregnancy.
Iron, in dietary, oral, and IV forms, has been found effective in resolving anemia in pregnancy. Pregnant people with IDA in the third trimester are more likely to benefit from IV iron. Future studies designed and powered to assess maternal and perinatal morbidity indicators and blood transfusion rates can strengthen recommendations.
妊娠期贫血与孕产妇及新生儿发病率增加相关。产科医生越来越意识到筛查缺铁性贫血(IDA)的必要性,关于其诊断和治疗的文献也在不断增加。本综述旨在总结妊娠期IDA的病因、后果、治疗及评估。
各国指南对妊娠期IDA的诊断和治疗提供了不同的指导。血清铁蛋白有助于IDA的诊断。口服铁剂仍是一种治疗选择;隔日给药可提高吸收率,对能够耐受的患者有效。关于新一代静脉注射(IV)铁剂的新研究表明,其输注时间更短,安全性更高。值得注意的是,英国最近的指南考虑对妊娠34周以上的贫血患者普遍补充静脉铁剂进行治疗。
已发现饮食中的铁、口服铁剂和静脉铁剂对解决妊娠期贫血有效。孕晚期患有IDA的孕妇更有可能从静脉铁剂中获益。未来设计并具备足够样本量以评估孕产妇和围产期发病率指标及输血率的研究可以强化相关建议。